Villere ST Denis J & Co. LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 136,419 shares of the company's stock after selling 2,287 shares during the quarter. Johnson & Johnson accounts for about 2.2% of Villere ST Denis J & Co. LLC's investment portfolio, making the stock its 26th largest position. Villere ST Denis J & Co. LLC's holdings in Johnson & Johnson were worth $22,624,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Tallon Kerry Patrick purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $290,000. Brighton Jones LLC increased its stake in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares during the last quarter. Hudson Value Partners LLC raised its holdings in shares of Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after acquiring an additional 1,022 shares in the last quarter. Allegiance Financial Group Advisory Services LLC boosted its position in Johnson & Johnson by 8.4% during the fourth quarter. Allegiance Financial Group Advisory Services LLC now owns 3,329 shares of the company's stock valued at $481,000 after purchasing an additional 258 shares during the last quarter. Finally, Schnieders Capital Management LLC grew its stake in Johnson & Johnson by 4.6% in the fourth quarter. Schnieders Capital Management LLC now owns 70,725 shares of the company's stock valued at $10,228,000 after purchasing an additional 3,120 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.
Johnson & Johnson Stock Performance
Johnson & Johnson stock traded up $0.17 on Monday, hitting $152.58. The company's stock had a trading volume of 9,000,393 shares, compared to its average volume of 8,022,753. The company has a fifty day moving average price of $153.75 and a 200-day moving average price of $153.81. The firm has a market cap of $367.12 billion, a P/E ratio of 16.97, a price-to-earnings-growth ratio of 2.31 and a beta of 0.42. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.41%. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is currently 57.84%.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on JNJ shares. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Bank of America decreased their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday, April 10th. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Finally, Royal Bank Of Canada reiterated an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Thursday, June 5th. Eleven analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $170.88.
View Our Latest Report on Johnson & Johnson
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
